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EVOLUTION OF PRESCRIPTIONS AND DRUG COSTS IN
HYPERTENSION—RESULTS FROM A DATABASE FOLLOW-UP
STUDY
Berger W1,Annemans L2
1Merck KGaA, Darmstadt, Germany; 2Ghent University, HEDM, Meise,
Belgium
OBJECTIVE: To compare the evolution of persistence rates and
drug costs in patients whose antihypertensive therapy was
started with a low-dose combination therapy or with various
monotherapies in daily practice. METHODS: Patients in the
Thalès database in France, whose therapy was started with 1) a
low-dose combination of bisoprolol and hydrochlorothiazide
(b/hctz); 2) angiotensin-II-antagonists (AIIA); 3) calcium-channel
blockers (CCB); or 4) angiotensin-converting enzyme inhibitors
(ACE) from January-August 2000, were followed up for 1.5
years. The prescriptions at inclusion and the ﬁnal prescriptions
in each subsequent quarter were recorded. Patients who
remained on their initial treatment were classiﬁed as persistent.
The average daily drug costs per patient (ADDC) were calculated
for all four groups at all measurement points based on public
prices in France. RESULTS: A total of 1587 patients were
included. The persistence rate at study end was 68.3% in the
low-dose b/hctz group, followed by the AIIA (57.2%), the CCB
(56.1%) and the ACE group (51.7%). Statistical signiﬁcance was
only reached between the b/hctz group and the ACE group (p <
0.01). Switches in therapy and the initiation of combination
treatments led to a steady increase in ADDC in the CCB, ACE
and b/hctz groups during follow-up (from 0.66€ to 0.90€, 0.76€
to 0.86€ and 0.45€ to 0.60€, respectively). In the AIIA group,
ADDC decreased slightly due to switches in therapy to lower-
priced drugs (1.08€ to 1.03€). Pairwise differences in ADDC
between the b/hctz group and all other groups reached signiﬁ-
cance at all measurement points (p < 0.01). CONCLUSION: Fre-
quent changes in treatment make it difﬁcult to predict the
evolution of daily drug costs in hypertension. In our study, the
ADDC in the b/hctz group were lower than in the three com-
parator groups at inclusion and remained lower after the effect
of treatment changes were taken into account.
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COSTS OF HYPERTENSION IN POLAND MEASURED FROM
THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON
WITH THE SOCIETAL PERSPECTIVE
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1Warsaw University of Technology, Warsaw, Poland; 2Servier Polska,
Warsaw, Poland
OBJECTIVE: To compare the costs of hypertension in Poland,
measured from the third party payer perspective and the societal
perspective. METHODS: The retrospective analysis of the 9286
patients’ records derived from a scientiﬁc project conducted
among GPs’ in the whole of Poland in the year 2000. The time
horizon was 12 months. Calculations were made from the third-
party payer perspective including costs of: drug reimbursement,
physicians’ consultations, laboratory, diagnostic tests and hospi-
talisation. The unit costs were obtained from the Polish National
Health Fund. Calculations from the societal perspective were
also made to evaluate patient expenditure on drugs and indirect
costs. RESULTS: Direct medical costs constituted 59% of the
total hypertension costs in Poland (214€ per patient per year),
16% of which represented the cost of pharmacological treat-
ment. Indirect costs (41%) amounted to 148€ per patient per
year. Assuming that 8.5 million Poles suffer from hypertension,
the total societal burden of hypertension could reach 1.53€
billion annually. From the third-party payer perspective, distrib-
ution of the costs was as follows: laboratory and diagnostic tests
21%, hospitalization 31%, physicians’ consultations, 37% and
drugs only 11%, because of an extremely high patient co-
payment rate of 67%. The total, annual third party payer burden
of hypertension amounted to 723€ million (172€ per patient),
which equalled 47.5% of the total societal costs, including indi-
rect costs. Assuming 400,000 new cases of hypertension annu-
ally, total costs related to the incidence of hypertension in Poland
could reach 65.7€ million. CONCLUSION: The costs of hyper-
tension impact on the third party payer and Polish society to the
same extent. High patient co-payment for antihypertensive drugs
and a relatively low reimbursement rate, lead to limited access
to innovative therapies, which may cause a gradual increase in
hypertension costs in Poland in the future.
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COSTS OF HYPERTENSION IN THE ELDERLY IN
COMPARISON WITH PATIENTS UNDER 65 IN POLAND
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1Warsaw University of Technology, Warsaw, Poland; 2Servier Polska,
Warsaw, Poland
OBJECTIVE: To compare the costs of hypertension in the elderly
with the costs in patients under 65 in Poland. METHODS: The
time horizon of the analysis was 12 months and a retrospective
approach was applied. Calculations were made from the societal
perspective. Direct medical costs of pharmacological treatment,
physicians’ consultations, laboratory, diagnostic tests and hospi-
talisation were identiﬁed and calculated. Indirect costs resulting
from productivity loss were also included in the analysis.
Resource utilisation data were derived from a scientiﬁc project
conducted among GPs’ in the whole of Poland in the year 2000.
The unit costs were obtained from the Polish National Health
Fund. RESULTS: The total annual direct medical cost per patient
in the elderly group was 15% higher than in the group of patients
under 65 and was equal to 239€. The distribution of the direct
medical costs in the elderly group was as follows: drugs 25%,
physicians’ consultations 28%, laboratory, diagnostic tests 21%
and hospitalisation 25%. Both physicians’ consultation costs
(68€ per patient per year) and hospitalisation costs (61€ per
patient per year) were higher in elderly group than in younger
patients (45% and 12% respectively). The indirect costs for
elderly patients were about ten times lower than in patients
under 65, which generated the costs of 214€ per patient per year.
CONCLUSION: The direct medical costs were higher in elderly
hypertensive patients. The indirect costs were higher in younger
hypertensive probably due to retirement at 60 for women and
65 for men in Poland. There are no differences between the com-
pared groups in expenditure on drugs and patients’ co-payment.
The trends observed may have a great impact on the total burden
of hypertension, because of the higher incidence of hypertension
in younger people and the aging of the Polish population.
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COST-EFFECTIVENESS ANALYSIS OF THE MANAGEMENT OF
ARTERIAL HYPERTENSION
Staﬁlas PC1, Saraﬁdis PA1, Lasaridis AN1,Aletras VH2, Zouka MD3
1AHEPA University Hospital,Thessaloniki, Greece; 2Hellenic Open
University, Patra, Greece; 3Aristotle University of Thessaloniki,
Thessaloniki, Greece
OBJECTIVE: The 5 major classes of antihypertensive agents are
suitable for the initiation and maintenance of antihypertensive
therapy according to 2003 European Society of Hypertension—
European Society of Cardiology guidelines. The aim of this study
was to compare the cost-effectiveness of these antihypertensive
agents in mild to moderate hypertension in Greece. METHODS:
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A Markov model, based on data from randomised trials, was
developed to compare the 5 alternative interventions: chlorthali-
done, propranolol, amlodipine, silazapril and losartan. A 
cost-effectiveness analysis was performed, based on numbers-
needed-to-treat (NNT) derived from a published metaanalysis.
The primary outcome measure was the NNT to prevent one fatal
cardiovascular disease event and the secondary outcome measure
was the NNT to prevent one stroke (fatal and nonfatal). Cost
data were derived from public sources. Only direct costs were
considered in the analysis. All costs were calculated from the per-
spective of the public insurance system organisations, in 2003
Euros. Future costs and clinical beneﬁts were discounted at 5%.
The time horizon was 5 years. Sensitivity analyses tested the
effect of modifying the input parameters on the economic end-
points. RESULTS: No signiﬁcant differences in efﬁcacy presented
among drug groups in mild to moderate hypertension. The NNT
for 5 years to prevent one fatal cardiovascular disease event 
was 135.27 patients and to prevent one stroke was just 
64.05 patients. The estimated total cost to prevent one fatal 
cardiovascular disease event was 78,121.40€, 84,040.63€,
118,825.36€, 103,098.82€, and 168,485.60€ for chlorthalidone,
propranolol, amlodipine, silazapril and losartan respectively. The
estimated total cost to prevent one stroke was 36,990.28€,
39,793.02€, 56,263.50€, 48,817.03€ and 79,777.50€ respec-
tively. Sensitivity analysis conﬁrmed the superiority of chlor-
thalidone against the other antihypertensive agents.
CONCLUSIONS: In mild to moderate hypertension, chlorthali-
done is more cost-effective than propranolol, amlodipine, silaza-
pril and losartan and should be considered as the ﬁrst choice of
antihypertensive therapy.
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COST EFFECTIVENESS OF ANTIHYPERTENSIVE MONO-
THERAPY WITH PERINDOPRIL OR ENALAPRIL IN ELDERLY
PATIENTS FROM THE THIRD PARTY PAYER PERSPECTIVE
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1Warsaw University of Technology, Warsaw, Poland; 2Servier Polska,
Warsaw, Poland
OBJECTIVE: To asses the economic consequences of antihyper-
tensive treatment with perindopril and enalapril in the elderly,
from the third-party payer perspective. METHODS: The clini-
cal, epidemiological and economic data were derived from a sci-
entiﬁc project conducted among GPs’ in the whole of Poland,
and concerned 159 patients over 65. treated in mono-therapy
within the last year. Calculations were made from the third-party
payer perspective. The retrospective approach was applied. The
direct medical costs of: drug reimbursement, physicians’ consul-
tations, hospitalisation, laboratory and diagnostic tests were
identiﬁed and calculated. Effectiveness was measured by the 
percentage of the patients with appropriately controlled blood
pressure (BP < 140/90mmHg) in accordance with JNC VII guide-
lines. RESULTS: The measured effectiveness of the mono-
therapy was 43% in the perindopril group and 24% in the
enalapril group. Cost of the hospitalisation in the perindopril
group was 54.95% lower than in the enalapril group, which is
equivalent to 89.52€ saved per patient per year. Physicians’ con-
sultations cost reduction in the perindopril group amounted to
15.18€ (21.59%) per patient per year. There was no signiﬁcant
difference in the costs of laboratory and diagnostic tests between
the compared treatments (30.93€ and 27.28€ respectively).
Treatment with perindopril requires additional payer’s expendi-
ture of 18.95€ per patient per year. Total costs measured from
the third-party payer perspective in the perindopril group, were
30.08% lower than in the enalapril group which equalled 82.10€
saved per each patient per year. CONCLUSION: Taking third-
party payer perspective into consideration, mono-therapy with
perindopril is superior to treatment with enalapril in elderly
patients due to better blood pressure control and essential
savings resulting mainly from the reduction of both hospitalisa-
tion and physicians’ consultation costs.
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ECONOMIC EVALUATION OF VARIOUS ANTIHYPERTENSIVE
MONOTHERAPIES IN GREECE
Staﬁlas PC1, Zouka MD2, Saraﬁdis PA1, Lasaridis AN1,Aletras VH3
1AHEPA University Hospital,Thessaloniki, Greece; 2Aristotle University
of Thessaloniki,Thessaloniki, Greece; 3Hellenic Open University, Patra,
Greece
OBJECTIVE: The purpose of this study was to compare the costs
associated with the prescription of various initial monotherapies
for mild to moderate hypertension in Greece, when following
2003 European Society of Hypertension—European Society of
Cardiology guidelines. In these guidelines, it is concluded that
the 5 major classes of antihypertensive agents are suitable for the
initiation and maintenance of antihypertensive therapy because
of their similar protection against total and cardiovascular mor-
tality. METHODS: A cost-minimization analysis was performed,
based on numbers-needed-to-treat (NNT) derived from a pub-
lished metaanalysis. An economic model was developed to
compare the 5 alternative interventions: diuretics (chlorthali-
done), â-blockers (propranolol), calcium-channel blockers
(amlodipine), angiotensin-converting enzyme inhibitors (silaza-
pril) and angiotensin receptor blockers (losartan). Cost data were
derived from public sources. Only direct costs were considered
in the analysis including the cost of drug therapy, monitoring,
treating side-effects, poor compliance and switching. All costs
were calculated from a third-party payer perspective, in 2003
Euros. Future costs were discounted at 5%. The time horizon
was 5 years. RESULTS: The total cost to achieve and maintain
hypertension control was 666.21€, 716.69€, 1013.32€, 879.21€,
and 1436.82€ for chlorthalidone, propranolol, amlodipine,
silazapril and losartan respectively. The drug acquisition cost was
20.85%, 29.98%, 53.30%, 45.65%, and 68.22% respectively.
Drug acquisition cost and cost of laboratory monitoring were
more than 85% of the total treatment cost for all the antihy-
pertensive agents. Sensitivity analysis tested the effect of modi-
fying the prices of the antihypertensive agents and laboratory
monitoring, the doses of the alternative drugs and the compli-
ance rate on the economic endpoints and conﬁrmed the superi-
ority of chlorthalidone. CONCLUSIONS: In mild to moderate
hypertension, the 5 major classes of antihypertensive agents
provide similar protection against total and cardiovascular mor-
tality, but diuretics are cheaper than the others. Diuretics should
be considered as the ﬁrst choice of antihypertensive treatment.
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THE COST EFFECTIVENESS OF HORMONE REPLACEMENT
THERAPY (HRT) FOR WOMEN WITH MENOPASUAL
SYMPTOMS IN SWEDEN
Borgström F1, Zethraeus N2, Johnell O3, Kanis J4, Jönsson B2
1Stockholm Health Economics, Stockholm, Sweden; 2Stockholm
School of Economics, Stockholm, Sweden; 3Malmö University
Hospital, Malmö, Sweden; 4University of Shefﬁeld, Shefﬁeld, UK
OBJECTIVES: Recent randomised studies have indicated that
Hormone Replacement Therapy (HRT) does not reduce the risk
of cardiovascular events neither in secondary nor in primary pre-
vention. Evidence of the effect of HRT on breast cancer has been
inconclusive, but now the general belief is that the risk of breast
cancer increases. In line with the results found in the Women’s
Health Initiative (WHI) the cost-effectiveness of HRT therapy,
